Brand names: Ozempic (diabetes), Wegovy (obesity)
Side effects - primarily gastrointestinal (nausea, vomiting, constipation, and abdominal discomfort) - are well-documented in clinical trial populations and are typically most pronounced during the initial titration phase before the body adapts to rising drug concentrations, which is why the standard-of-care approach involves gradual dose escalation over several weeks or months rather than starting at full therapeutic dose
No specific outcomes are guaranteed
Some companies, such as Mochi Health, require patients to meet virtually with a provider, such as a doctor, nurse practitioner, or physician assistant, before they can get a GLP-1 prescription
References IAPAM
You will be unlikely to lose weight as quickly by naturally activating GLP-1 versus Ozempic